Possibilities of Early Combination Therapy with Sitagliptin and Metformin in the Correction of Metabolic Disorders in Patients with Type 2 Diabetes and Obesity

Ametov Alexander Sergeevich; Gusenbekova Dinara Gadjimagomedovna; Butaeva Svetlana Garrievna; P'yanykh Olga Pavlovna

doi:doi:10.11648/j.ijde.20200501.11

| Peer-Reviewed

Possibilities of Early Combination Therapy with Sitagliptin and Metformin in the Correction of Metabolic Disorders in Patients with Type 2 Diabetes and Obesity

Ametov Alexander Sergeevich, Gusenbekova Dinara Gadjimagomedovna, Butaeva Svetlana Garrievna, P'yanykh Olga Pavlovna

Published in International Journal of Diabetes and Endocrinology (Volume 5, Issue 1)

Received: 23 November 2019 Accepted: 2 January 2020 Published: 9 January 2020

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Diabetes mellitus is one of the most common diseases of the endocrine system that is encountered in the practice of any doctor in any specialty. Some features of type 2 diabetes are: a slow progressive development and a mild clinical picture in the early stages of the development of the disease. The main goal of diabetes treatment is to prevent the development of late complications that reduce the quality of life of patients, leading to their early disability and death. Despite the increase in the number of antihyperglycemic drugs in the pharmaceutical industry, we are still not successful enough to achieve good glycemic control. In addition, achieving good glycemic control does not always prevent macrovascular complications in patients with diabetes mellitus. The article presents the results of two studies. The first study examined the diurnal fluctuations in blood glucose levels during therapy with type 4 dipeptidyl peptidase inhibitor Sitagliptin, as well as its effect on oxidative stress markers in comparison with MV gliclazide. The second study examined the role of sitagliptin in the correction of disorders of fat metabolism.

Published in	International Journal of Diabetes and Endocrinology (Volume 5, Issue 1)
DOI	10.11648/j.ijde.20200501.11
Page(s)	1-5
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2020. Published by Science Publishing Group

Keywords

Diabetes, Obesity, Sitagliptin, Fat Metabolism, Glucose Monitoring

References

[1]	Nathan R. Hill, DPhil, Nick S. Oliver, Pratik Choudhary. Normal Reference Range for Mean Tissue Glucose and Glycemic Variability Derived from Continuous Glucose Monitoring for Subjects Without Diabetes in Different Ethnic Groups. Diabetes technology & therapeutics. 2011 Sep; 13 (9): 921–928. doi: 10.1089/dia.2010.0247.
[2]	Bonora E, Calcaterra F, Lombardi S, Bonfante N, Formentini G, Bonadonna RC, Muggeo M. Plasma glucose levels throughout the day and HbA (1c) interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care. 2001. Vol. 24. № 12. P. 2023–2029. doi.org/10.2337/diacare.24.12.2023.
[3]	Standl E, Schnell O, Ceriello A. Postprandial hyperglycemia and glycemic variability: should we care? Diabetes Care. 2011 May; 34 Suppl. 2: S120-7. doi: 10.2337/dc11-s206.
[4]	Kashiwagi AL, Asahina T, Nishio Y. Glycation, oxidative stress, and scavenger activity: glucose metabolism and radical scavenger dysfunction in endothelial cells. Diabetes. 1996 Jul; 45 Suppl. 3: S84-6.doi: https://www.ncbi.nlm.nih.gov/pubmed/8674901.
[5]	Tonooka N, Oseid E, Zhou H, Harmon JS, Robertson RP. Glutathione peroxidase protein expression and activity in human islets isolated for transplantation. Clinical Transplantation. 2007 Nov-Dec; 21 (6): 767-72. doi 10.1111/j.1399-0012.2007.00736.x.
[6]	Pankratova MA, Pirozhkov SV, Balabolkin MI, Litvicki PF. Oxidative stress in patients with type 2 diabetes mellitus with different duration of the disease and varying degrees of compensation for carbohydrate metabolism. Diabetes mellitus. 2/2006, P. 12-15. doi: http://dx.doi.org/10.14341/2072-0351-6113.
[7]	Van Genugten R. Moller-Goede D., van Raatle D. et al Extrapancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes / Diabetes, Obesity and Metabolism-2013-№7: 593606.
[8]	Jose T. Inzucchi S. Cardiovascular effects of the DPP-4 inhibitors. Diabetes and Vascular Disease Research-2012№2: 109-116.
[9]	Satoh-Asahara N. Sasaki Y., Wada H. et al. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Metabolism-2013-№3: 347351.
[10]	Derosa G. Ragonesi P., Fogaria E. at al. Sitagliptin added to previously taken anti-diabetic agents on insulin resistance and lipid profile: a two years study evaluation. Fundam Clin Pharmacol-2012-№2: 221-229.
[11]	Nomura K, Saitoh T, Kim GU et al. Glycemic Profiles of Healthy Individuals with Low Fasting Plasma Glucose and HbA1c. ISRN Endocrinology. Volume 2011 (2011), Article ID 435047, 6 pages http://dx.doi.org/10.5402/2011/435047.
[12]	Ametov A. S., Gusenbekova D. G. The role of DPP-4 inhibitors in the correction of fat metabolism disorders in patients with type 2 diabetes and obesity. Diabetes mellitus. 2015; 18 (3): 8592.
[13]	https://www.intechopen.com/books/diabetes-and-its-complications/dpp-4-inhibitors-and-fatmetabolism-in-patients-with-type-2-diabetes.
[14]	Ametov A. S., Gusenbekova D. G. International Journal of Clinical and Experimental Medical Sciences. Volume 4, Issue 6, November 2018, Pages: 78-86.
[15]	Hill NR, Nick SO, Choudhary P et al. Normal Reference Range for Mean Tissue Glucose and Glycemic Variability Derived from Continuous Glucose Monitoring for Subjects Without Diabetes in Different Ethnic Groups Diabetes// Technology & Therapeutics. August 2011, 13 (9): 921-928. doi: 10.1089/dia.2010.0247.
[16]	O’Brien R. C, Luo M, Balazs N. et al. In-vitro and in-vivo antioxidant properties of gliclazide. Journal of Diabetes and its Complications. 2000. Vol. 14. P. 201–206 doi: http://dx.doi.org/10.1016/S1056-8727(00)00084-2.
[17]	Pocai A., Carrington P., Adams J., et al. Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice. Diabetes.-№10-2009: 2258–2266.
[18]	Kim Ch., Hosaka T., Yoshida M. et al. Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochemical and Biophysical Research Communications - 2009-№3: 613–618.
[19]	Nomura Sh., Omoto S., Taniura T. et al. Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - 2015: 339.
[20]	Nagao H., Kashine S., Nishizawa H., et al. Vascular complications and changes in body mass index in Japanese type 2 diabetic patients with abdominal obesity. Cardiovascular Diabetology - 2013-№1: 88.

Cite This Article

Plain Text BibTeX RIS

APA Style

Ametov Alexander Sergeevich, Gusenbekova Dinara Gadjimagomedovna, Butaeva Svetlana Garrievna, P'yanykh Olga Pavlovna. (2020). Possibilities of Early Combination Therapy with Sitagliptin and Metformin in the Correction of Metabolic Disorders in Patients with Type 2 Diabetes and Obesity. International Journal of Diabetes and Endocrinology, 5(1), 1-5. https://doi.org/10.11648/j.ijde.20200501.11

Copy | Download

ACS Style

Ametov Alexander Sergeevich; Gusenbekova Dinara Gadjimagomedovna; Butaeva Svetlana Garrievna; P'yanykh Olga Pavlovna. Possibilities of Early Combination Therapy with Sitagliptin and Metformin in the Correction of Metabolic Disorders in Patients with Type 2 Diabetes and Obesity. Int. J. Diabetes Endocrinol. 2020, 5(1), 1-5. doi: 10.11648/j.ijde.20200501.11

Copy | Download

AMA Style

Ametov Alexander Sergeevich, Gusenbekova Dinara Gadjimagomedovna, Butaeva Svetlana Garrievna, P'yanykh Olga Pavlovna. Possibilities of Early Combination Therapy with Sitagliptin and Metformin in the Correction of Metabolic Disorders in Patients with Type 2 Diabetes and Obesity. Int J Diabetes Endocrinol. 2020;5(1):1-5. doi: 10.11648/j.ijde.20200501.11

Copy | Download

@article{10.11648/j.ijde.20200501.11,
  author = {Ametov Alexander Sergeevich and Gusenbekova Dinara Gadjimagomedovna and Butaeva Svetlana Garrievna and P'yanykh Olga Pavlovna},
  title = {Possibilities of Early Combination Therapy with Sitagliptin and Metformin in the Correction of Metabolic Disorders in Patients with Type 2 Diabetes and Obesity},
  journal = {International Journal of Diabetes and Endocrinology},
  volume = {5},
  number = {1},
  pages = {1-5},
  doi = {10.11648/j.ijde.20200501.11},
  url = {https://doi.org/10.11648/j.ijde.20200501.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijde.20200501.11},
  abstract = {Diabetes mellitus is one of the most common diseases of the endocrine system that is encountered in the practice of any doctor in any specialty. Some features of type 2 diabetes are: a slow progressive development and a mild clinical picture in the early stages of the development of the disease. The main goal of diabetes treatment is to prevent the development of late complications that reduce the quality of life of patients, leading to their early disability and death. Despite the increase in the number of antihyperglycemic drugs in the pharmaceutical industry, we are still not successful enough to achieve good glycemic control. In addition, achieving good glycemic control does not always prevent macrovascular complications in patients with diabetes mellitus. The article presents the results of two studies. The first study examined the diurnal fluctuations in blood glucose levels during therapy with type 4 dipeptidyl peptidase inhibitor Sitagliptin, as well as its effect on oxidative stress markers in comparison with MV gliclazide. The second study examined the role of sitagliptin in the correction of disorders of fat metabolism.},
 year = {2020}
}

Copy | Download

TY  - JOUR
T1  - Possibilities of Early Combination Therapy with Sitagliptin and Metformin in the Correction of Metabolic Disorders in Patients with Type 2 Diabetes and Obesity
AU  - Ametov Alexander Sergeevich
AU  - Gusenbekova Dinara Gadjimagomedovna
AU  - Butaeva Svetlana Garrievna
AU  - P'yanykh Olga Pavlovna
Y1  - 2020/01/09
PY  - 2020
N1  - https://doi.org/10.11648/j.ijde.20200501.11
DO  - 10.11648/j.ijde.20200501.11
T2  - International Journal of Diabetes and Endocrinology
JF  - International Journal of Diabetes and Endocrinology
JO  - International Journal of Diabetes and Endocrinology
SP  - 1
EP  - 5
PB  - Science Publishing Group
SN  - 2640-1371
UR  - https://doi.org/10.11648/j.ijde.20200501.11
AB  - Diabetes mellitus is one of the most common diseases of the endocrine system that is encountered in the practice of any doctor in any specialty. Some features of type 2 diabetes are: a slow progressive development and a mild clinical picture in the early stages of the development of the disease. The main goal of diabetes treatment is to prevent the development of late complications that reduce the quality of life of patients, leading to their early disability and death. Despite the increase in the number of antihyperglycemic drugs in the pharmaceutical industry, we are still not successful enough to achieve good glycemic control. In addition, achieving good glycemic control does not always prevent macrovascular complications in patients with diabetes mellitus. The article presents the results of two studies. The first study examined the diurnal fluctuations in blood glucose levels during therapy with type 4 dipeptidyl peptidase inhibitor Sitagliptin, as well as its effect on oxidative stress markers in comparison with MV gliclazide. The second study examined the role of sitagliptin in the correction of disorders of fat metabolism.
VL  - 5
IS  - 1
ER  -

Copy | Download

Author Information

Ametov Alexander Sergeevich

Russian Medical Academy of Continuing Professional Education, Moscow, Russia
Gusenbekova Dinara Gadjimagomedovna

Russian Medical Academy of Continuing Professional Education, Moscow, Russia
Butaeva Svetlana Garrievna

Russian Medical Academy of Continuing Professional Education, Moscow, Russia
P'yanykh Olga Pavlovna

Russian Medical Academy of Continuing Professional Education, Moscow, Russia

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Ametov Alexander Sergeevich, Gusenbekova Dinara Gadjimagomedovna, Butaeva Svetlana Garrievna, P'yanykh Olga Pavlovna. (2020). Possibilities of Early Combination Therapy with Sitagliptin and Metformin in the Correction of Metabolic Disorders in Patients with Type 2 Diabetes and Obesity. International Journal of Diabetes and Endocrinology, 5(1), 1-5. https://doi.org/10.11648/j.ijde.20200501.11

Copy | Download

ACS Style

Ametov Alexander Sergeevich; Gusenbekova Dinara Gadjimagomedovna; Butaeva Svetlana Garrievna; P'yanykh Olga Pavlovna. Possibilities of Early Combination Therapy with Sitagliptin and Metformin in the Correction of Metabolic Disorders in Patients with Type 2 Diabetes and Obesity. Int. J. Diabetes Endocrinol. 2020, 5(1), 1-5. doi: 10.11648/j.ijde.20200501.11

Copy | Download

AMA Style

Ametov Alexander Sergeevich, Gusenbekova Dinara Gadjimagomedovna, Butaeva Svetlana Garrievna, P'yanykh Olga Pavlovna. Possibilities of Early Combination Therapy with Sitagliptin and Metformin in the Correction of Metabolic Disorders in Patients with Type 2 Diabetes and Obesity. Int J Diabetes Endocrinol. 2020;5(1):1-5. doi: 10.11648/j.ijde.20200501.11

Copy | Download

@article{10.11648/j.ijde.20200501.11,
  author = {Ametov Alexander Sergeevich and Gusenbekova Dinara Gadjimagomedovna and Butaeva Svetlana Garrievna and P'yanykh Olga Pavlovna},
  title = {Possibilities of Early Combination Therapy with Sitagliptin and Metformin in the Correction of Metabolic Disorders in Patients with Type 2 Diabetes and Obesity},
  journal = {International Journal of Diabetes and Endocrinology},
  volume = {5},
  number = {1},
  pages = {1-5},
  doi = {10.11648/j.ijde.20200501.11},
  url = {https://doi.org/10.11648/j.ijde.20200501.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijde.20200501.11},
  abstract = {Diabetes mellitus is one of the most common diseases of the endocrine system that is encountered in the practice of any doctor in any specialty. Some features of type 2 diabetes are: a slow progressive development and a mild clinical picture in the early stages of the development of the disease. The main goal of diabetes treatment is to prevent the development of late complications that reduce the quality of life of patients, leading to their early disability and death. Despite the increase in the number of antihyperglycemic drugs in the pharmaceutical industry, we are still not successful enough to achieve good glycemic control. In addition, achieving good glycemic control does not always prevent macrovascular complications in patients with diabetes mellitus. The article presents the results of two studies. The first study examined the diurnal fluctuations in blood glucose levels during therapy with type 4 dipeptidyl peptidase inhibitor Sitagliptin, as well as its effect on oxidative stress markers in comparison with MV gliclazide. The second study examined the role of sitagliptin in the correction of disorders of fat metabolism.},
 year = {2020}
}

Copy | Download

TY  - JOUR
T1  - Possibilities of Early Combination Therapy with Sitagliptin and Metformin in the Correction of Metabolic Disorders in Patients with Type 2 Diabetes and Obesity
AU  - Ametov Alexander Sergeevich
AU  - Gusenbekova Dinara Gadjimagomedovna
AU  - Butaeva Svetlana Garrievna
AU  - P'yanykh Olga Pavlovna
Y1  - 2020/01/09
PY  - 2020
N1  - https://doi.org/10.11648/j.ijde.20200501.11
DO  - 10.11648/j.ijde.20200501.11
T2  - International Journal of Diabetes and Endocrinology
JF  - International Journal of Diabetes and Endocrinology
JO  - International Journal of Diabetes and Endocrinology
SP  - 1
EP  - 5
PB  - Science Publishing Group
SN  - 2640-1371
UR  - https://doi.org/10.11648/j.ijde.20200501.11
AB  - Diabetes mellitus is one of the most common diseases of the endocrine system that is encountered in the practice of any doctor in any specialty. Some features of type 2 diabetes are: a slow progressive development and a mild clinical picture in the early stages of the development of the disease. The main goal of diabetes treatment is to prevent the development of late complications that reduce the quality of life of patients, leading to their early disability and death. Despite the increase in the number of antihyperglycemic drugs in the pharmaceutical industry, we are still not successful enough to achieve good glycemic control. In addition, achieving good glycemic control does not always prevent macrovascular complications in patients with diabetes mellitus. The article presents the results of two studies. The first study examined the diurnal fluctuations in blood glucose levels during therapy with type 4 dipeptidyl peptidase inhibitor Sitagliptin, as well as its effect on oxidative stress markers in comparison with MV gliclazide. The second study examined the role of sitagliptin in the correction of disorders of fat metabolism.
VL  - 5
IS  - 1
ER  -

Copy | Download